{
    "root": "d360aaf2-0e56-4626-8bcf-7d480909a15a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Telisotuzumab Vedotin",
    "value": "20250514",
    "ingredients": [
        {
            "name": "TELISOTUZUMAB VEDOTIN",
            "code": "976X9VXC3Z"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        }
    ],
    "indications": "emrelis indicated treatment adult patients locally advanced metastatic , non-squamous non-small cell lung cancer ( nsclc ) high c-met protein overexpression [ ≥50 % tumor cells strong ( 3+ ) staining ] , determined fda-approved test [ ( 2.1 ) ] , received prior systemic therapy . indication approved accelerated approval based overall response rate ( orr ) duration response ( dor ) [ ( 14 ) ] . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) .",
    "contraindications": "intravenous infusion . ( 2.5 ) recommended emrelis 1.9 mg/kg administered intravenously every 2 weeks disease progression unacceptable toxicity . ( 2.2 ) reconstitute dilute emrelis prior intravenous infusion . ( 2.5 )",
    "warningsAndPrecautions": "supplied emrelis ( telisotuzumab vedotin-tllv ) injection sterile , preservative-free , white off-white lyophilized powder , supplied glass single-dose vial . carton one 20 mg/vial ( ndc 0074-1044-01 ) carton one 100 mg/vial ( ndc 0074-1055-01 ) storage handling store refrigerated 2oc 8oc ( 36of 46of ) original carton protect light . freeze . shake . special handling emrelis hazardous product . follow special handling disposal procedures.1",
    "adverseReactions": "none .",
    "indications_original": "EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration (\n                     \n                        2.1\n                     \n                     )], who have received a prior systemic therapy.\n                  \n                  This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies (\n                     \n                        14\n                     \n                     )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",
    "contraindications_original": "For intravenous infusion only. ( 2.5 ) The recommended dosage of EMRELIS is 1.9 mg/kg administered intravenously every 2 weeks until disease progression or unacceptable toxicity. ( 2.2 ) Reconstitute and further dilute EMRELIS prior to intravenous infusion. ( 2.5 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  EMRELIS (telisotuzumab vedotin-tllv) for injection is a sterile, preservative-free, white to off-white lyophilized powder, supplied in a glass single-dose vial.\n                  \n                     Carton of one 20 mg/vial (NDC 0074-1044-01)\n                     \n                     Carton of one 100 mg/vial (NDC 0074-1055-01)\n                  \n                  \n                     Storage and Handling\n                  \n                  Store refrigerated at 2oC to 8oC (36oF to 46oF) in original carton to protect from light. Do not freeze. Do not shake.\n                  \n                     Special Handling\n                  \n                  EMRELIS is a hazardous product. Follow special handling and disposal procedures.1",
    "adverseReactions_original": "None."
}